Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M. Hamilton A, et al. Among authors: van vreckem a. Clin Breast Cancer. 2000 Oct;1(3):233-40; discussion 241-2. doi: 10.3816/CBC.2000.n.020. Clin Breast Cancer. 2000. PMID: 11899648 Clinical Trial.
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. Among authors: van vreckem a. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P, Klijn J. Hamilton A, et al. Among authors: van vreckem a. Breast Cancer Res Treat. 2000 Mar;60(2):181-8. doi: 10.1023/a:1006398518037. Breast Cancer Res Treat. 2000. PMID: 10845281 Clinical Trial.
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. Among authors: van vreckem a. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Paridaens R, Roy JA, Nooij M, Klijn J, Houston SJ, Beex LV, Vinholes J, Tomiak E, Van Vreckem A, Langenaeken C, Van Glabbeke M, Piccart MJ. Paridaens R, et al. Among authors: van vreckem a. Anticancer Drugs. 1998 Jan;9(1):29-35. doi: 10.1097/00001813-199801000-00003. Anticancer Drugs. 1998. PMID: 9491789 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J. Tabernero J, et al. Among authors: van vreckem a. J Clin Oncol. 2005 Apr 10;23(11):2521-33. doi: 10.1200/JCO.2005.00.398. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710949 Clinical Trial.
11 results